Biomarkers Of Chronic Disease Research Articles

Specific and Magnetic Covalent Organic Framework Confined Os Nanoclusterzyme for Interference‐Free and Ultrasensitive Biosensing

AbstractThe peroxidase (POD)‐mimic nanozymes can be a potential tool for point‐of‐care (POC) diseases diagnosis. However, the complex sample matrix and unspecific multiple‐enzyme activities of nanozyme can generate false background signal and decrease the diagnostic accuracy. Here, a magnetic and POD‐specific covalent organic framework (COF) confined osmium (Os) nanoclusterzyme Fe3O4@COF@Os is developed for biomarkers biosensing. First, found that the catalytic activity and specificity of Fe3O4@COF@Os can be regulated by the deoxidizers and the functional groups of COF ligands. By using ascorbic acid as deoxidizer and F functional COF ligands, Fe3O4@COF@Os displayed superior POD‐specific activity and negligible oxidase (OXD) and catalase (CAT) mimic activity. Therefore, Fe3O4@COF@Os can separate and analyze of targets in bio‐matrix without background interference. For application, Fe3O4@COF@Os based lateral flow assay is established for serum cancer biomarker prostate‐specific antigen, the detection limit is 3.83 pg mL−1. For clinical prostatic cancer samples, the accuracy is 100% with a correlation coefficient of 0.998 with commercial ELISA kit. For chronic disease biomarker sensing, salivary glucose can be quantified as low as 0.1 µm, with negligible background interference and favorable recyclability. This specific magnetic nanozymes can offer a promising pretreatment‐free and POC strategy for rapid and accurate diseases diagnosis.

Metabolomic and genomic insights into TMA degradation by a novel halotolerant strain - Paracoccus sp. PS1.

Trimethylamine N-oxide (TMAO) is a gut metabolite that acts as a biomarker for chronic diseases, and is generated by the oxidation of trimethylamine (TMA) produced by gut microflora. Since, microbial degradation of TMA is predicted to be used to restrict the production of TMAO, we aimed to isolate bacterial strains that could effectively degrade TMA before being oxidized to TMAO. As marine fish is considered to have a rich content of TMAO, we have isolated TMA degrading isolates from fish skin. Out of the fourteen isolates, depending on their rapid TMA utilization capability in mineral salt medium supplemented with TMA as a sole carbon and nitrogen source, isolate PS1 was selected as our desired isolate. Its TMA degrading capacity was further confirmed through spectrophotometric, Electrospray Ionization Time-of-Flight Mass Spectrometry (ESI TOF-MS) and High performance liquid chromatography (HPLC) analysis and in silico analysis of whole genome (WG) gave further insights of protein into its TMA degradation pathways. PS1 was taxonomically identified as Paracoccus sp. based on its 16S rRNA and whole genome sequence analysis. As PS1 possesses the enzymes required for degradation of TMA, clinical use of this isolate has the potential to reduce TMAO generation in the human gut.

Multiple urinary peptides are associated with hypertension: a link to molecular pathophysiology.

Hypertension is a common condition worldwide; however, its underlying mechanisms remain largely unknown. This study aimed to identify urinary peptides associated with hypertension to further explore the relevant molecular pathophysiology. Peptidome data from 2876 individuals without end-organ damage were retrieved from the Human Urinary Proteome Database: general population (discovery) or type 2 diabetic (validation) cohorts. Participants were divided based on systolic blood pressure (SBP) and diastolic BP (DBP) into hypertensive (SBP ≥140 mmHg and/or DBP ≥90 mmHg) and normotensive (SBP <120 mmHg and DBP <80 mmHg, without antihypertensive treatment) groups. Differences in peptide abundance between the two groups were confirmed using an external cohort (n = 420) of participants without end-organ damage, matched for age, BMI, eGFR, sex, and the presence of diabetes. Furthermore, the association of the peptides with BP as a continuous variable was investigated. The findings were compared with peptide biomarkers of chronic diseases and bioinformatic analyses were conducted to highlight the underlying molecular mechanisms. Between hypertensive and normotensive individuals, 96 (mostly COL1A1 and COL3A1) peptides were found to be significantly different in both the discovery (adjusted) and validation (nominal significance) cohorts, with consistent regulation. Of these, 83 were consistently regulated in the matched cohort. A weak, yet significant, association between their abundance and standardized BP was also observed. Hypertension is associated with an altered urinary peptide profile with evident differential regulation of collagen-derived peptides. Peptides related to vascular calcification and sodium regulation were also affected. Whether these modifications reflect the pathophysiology of hypertension and/or early subclinical organ damage requires further investigation.

Dietary Energy Density Is Associated with Biomarkers of Chronic Diseases—A Cross-Sectional Study of School-Aged Children in Rural Mexico

BackgroundDietary energy density (DED) is associated with chronic disease markers in adults. However, results in children are still controversial. ObjectiveTo evaluate the DED of children and its association with obesity and biomarkers of chronic disease. MethodsIn this cross-sectional study, we recruited 284 children (6–10 y) from rural Mexico. Dietary intake was assessed using three 24-h recalls. DED was calculated for “foods only” (DEDfo) and for “foods and beverages” (DEDfb). Weight, height, and body fat percent (dual-energy X-ray absorptiometry) were measured. Inflammatory cytokines, lipid profile, leptin, and insulin resistance were determined from a fasting blood sample. ResultsDEDfo was 1.91 ± 0.36 kcal/g and DEDfb was 1.36 ± 0.31 kcal/g. Higher DEDfo and DEDfb were associated with higher risk to have insulin resistance [odds ratio (OR) = 3.92, 95% confidence interval (CI): 1.66, 9.22, P < 0.01; OR = 3.51, 95% CI: 1.25, 9.87, P = 0.02, respectively]. Higher DEDfo was associated with higher risk of higher leptin levels (OR = 3.17, 95% CI: 1.01, 10.23). Also, DEDfo and DEDfb were associated with higher concentrations of cholesterol (β = 11.67, 95% CI: 1.81, 19.53, P = 0.03; and β = 11.74, 95% CI: 2.69, 20.74 P = 0.01, respectively) and higher odds of having high insulin concentrations (OR = 2.52, 95% CI: 1.26, 5.06, P = 0.01; and OR = 2.95, 95% CI: 1.30, 6.70, P = 0.01). DEDfo and DEDfb were not associated with any measure of obesity and inflammatory cytokines in the adjusted models. ConclusionsDED was associated with higher leptin and cholesterol concentrations, and having insulin resistance, but not with any measure of obesity or inflammation. Reducing DED may reduce risk of cardiovascular disease and improve insulin sensitivity in school-aged children.

Nuts and seeds - a scoping review for Nordic Nutrition Recommendations 2023.

Nuts and seeds have been part of diets in most of the world for millenniums, and they have also been consumed in the Nordic and Baltic countries for centuries. Consumption of nuts and seeds is linked with various health outcomes. Therefore, when updating the Nordic Nutrition Recommendations (NNR), summarizing the best evidence on key health outcomes from the consumption of nuts and seeds is essential. This study aims to evaluate the updated evidence on the consumption of nuts and seeds and health outcomes regarded relevant for the Nordic and Baltic countries, as well as their dose-response relationship presented in updated systematic reviews and meta-analyses. The scoping review is built on a de novo systematic review and an umbrella review published in 2022 on the consumption of nuts and seeds and its various health outcomes, including cardiovascular disease and diabetes. Intake of nuts and seeds is associated with a lower risk of cardiovascular diseases, with evidence assessed as probable. This conclusion is mirrored by evidence from trials on biomarkers for chronic diseases. An intake of a serving of nuts of 28-30 g/day compared to not eating nuts is estimated to translate into approximately 20% relative reduction in the risks of cardiovascular disease and premature deaths. For cancers, consumption of a serving of nuts is inversely associated with cancer mortality. However, for type 2 diabetes, there are mixed and inconclusive results. Additionally, there are inverse associations between nut consumption and respiratory and infectious disease mortality. Allergies for nuts are seen among 1-2% of the population. Overall, the current evidence supports dietary recommendations to increase nut consumption to a serving of nuts and seeds per day for people without allergies to these foods.

Combined effects of vitamin D deficiency and systemic inflammation on all-cause mortality and cause-specific mortality in older adults

BackgroundVitamin D deficiency and systemic inflammation share common pathological mechanisms in muscle loss, cardio-pulmonary function decline, and abnormal metabolism, which are linked to chronic conditions, senescence, and early mortality. However, their combined effect on mortality in older adults has not been well established. This study longitudinal aimed to explore the independent and combined associations of serum 25-hydroxyvitamin D [25(OH)D] and high sensitivity C-reactive protein (hs-CRP) with mortality risk in Chinese community-based older people.Methods3072 older adults (86.07 ± 11.87 years, 54.52% female) from the Chinese Longitudinal Healthy Longevity Survey (2012–2018) were enrolled. Baseline 25(OH)D and hs-CRP levels were collected, and survival information was recorded in the 2014 and 2018 follow-up waves. Cox proportional hazard regressions were conducted to explore the associations between 25(OH)D, hs-CRP, and mortality. Demographic characteristics, health behaviors, and chronic disease biomarkers were adjusted.ResultsDuring 10,622.3 person-years of follow-up (median: 3.51 years), 1321 older adults died, including 448 deaths due to cardiovascular disease (CVD). Increased mortality risk was associated with lower 25(OH)D and higher hs-CRP quantiles, even after adjusting for each other and multiple covariates (all P-trend < 0.05). In combined analyses, the highest all-cause mortality (HR: 2.18, 95% CI: 1.73 ~ 2.56), CVD mortality (HR: 2.30, 95% CI: 1.64 ~ 3.21), and non-CVD mortality (HR: 2.19, 95% CI: 1.79 ~ 2.49) were obtained in participants with both 25(OH)D deficiency (< 50 nmol/L) and high hs-CRP (≥ 3.0 mg/L), respectively. We observed significant additive interactions of 25(OH)D and hs-CRP on all-cause mortality and non-CVD mortality (RERIS>0).ConclusionsLow 25(OH)D and high hs-CRP, both independently and jointly, increase mortality risk in Chinese community-dwelling older adults. Thus, priority should be given to early detection and appropriate intervention in older individuals with combined vitamin D deficiency and systemic inflammation. Molecular mechanisms of related adverse health effect are worthy of further investigation.

Associations of bone mineral density with sex hormone-binding globulin (SHBG) and testosterone in middle-aged Saudi men: a cross-sectional study.

The present cross-sectional study examined the association between circulating levels of sex hormone-binding globulin (SHBG) and testosterone with bone mineral density (BMD) in middle-aged Arab men. Clinical data of 103 middle-aged Saudi men (mean age 60.7±7.2) were extracted from the Osteoporosis Registry of the Chair for Biomarkers of Chronic Diseases, King Saud University in Riyadh, Saudi Arabia. Participants were categorized according to the presence of osteopenia (T-score -1.0 to -2.5) (N=47) and controls (N=56). Data collected included demographics and anthropometrics as well as levels of sex hormone-binding globulin (SHBG), testosterone and follicle-stimulating hormone (FSH) which were measured using commercially available assays. Free androgen index (FAI) was calculated. Those with osteopenia had significantly lower levels of FAI (p<0.05), and higher levels of SHBG (p<0.004) and FSH (p<0.005). In the osteopenia group, SHBG was positively correlated with age (r=0.33, p<0.05), while it was inversely correlated with BMD spine (r = -0.39, p<0.05) and T-score femur (r= -0.35, p<0.05) in the same group. Furthermore, testosterone was inversely correlated with BMI in the osteopenia group (r= -0.33, p<0.05) while FAI was positively correlated with T-score femur (r = 0.36, p<0.05) as well as in all participants (r= 0.24, p<0.05). Among controls, FAI had an inverse correlation with FSH (r= -0.28, p<0.05) and over-all (r= -0.22, p<0.05). In summary, the associations elicited suggest that circulating levels of SHBG and FAI may be against age-related bone loss in middle-aged men.

Point-of-care testing of four chronic disease biomarkers in blood based on a low cost and low system complexity microfluidic chip with integrated oxygen-sensitive membrane

Point-of-care testing (POCT) of multiple chronic disease biomarkers is crucial for effective prevention and management of chronic diseases. Here, we developed a sensing platform based on microfluidics chip and oxygen-sensitive membrane (OSM), which utilized enzymatic oxygen consumption and OSM based signal conversion for portable detection of glucose, total cholesterol, uric acid, and triglyceride in blood. Their detection limits were 0.04 mM, 0.07 mM, 0.01 mM, and 0.05 mM, respectively, meeting clinical requirements. To avoid the reliance on laboratory equipment, a handheld mini centrifuge modified from a toy fan was developed for plasma separation and a smartphone was used for signal acquisition. In addition, signal conversion based OSM simplified reagent composition. Dry storage of reagents on the chip simplified operations and improved the stability of reagents. For chronic disease biomarkers in blood, the results obtained by our chips were consistent with commercial kits. We believe that this sensitive, low-cost, equipment-free sensing platform has a significant potential in self-management of chronic diseases.

A biosensing array for multiplex clinical evaluation of glucose, creatinine, and uric acid

The multiplex and simultaneous determination of blood glucose, creatinine and uric acid is essential for the early screening of chronic diseases or regular disease monitoring. Here, we report for the first time a biosensing array for the multiplex and simultaneous determination of plasma glucose, creatinine and uric acid. The sensing electrodes are fabricated on a PET surface, including three working electrodes, one reference electrode, and one counter electrode. Each specific enzyme is immobilized on its corresponding working electrode. The biosensing array can exhibit high sensitivity and selectivity for the simultaneous determination of blood glucose, creatinine and uric acid in real blood samples, and the measurement results are accurate and consistent with those from the clinical biochemistry analyzer in the hospital. It is expected that this work could provide new avenues for the fundamental study of biosensing device construction, as well as practical applications of the detection of biomarkers in chronic diseases.

Design of Aptamer-Based Optical Nanosensors for the Detection of Interleukin-6

Interleukin-6 (IL-6) is an inflammatory cytokine that has been recognized as a potential target for various autoimmune diseases, chronic inflammatory conditions, cancers, and more. Dysregulation of IL-6 is implicated in the genesis and progression of these disease states. For these reasons, detection of IL-6 and related biomolecules in vivo is of clinical interest to researchers of cancer and other inflammatory diseases. Single-walled carbon nanotubes (SWCNT) possess unique near-infrared fluorescent properties. When functionalized with a molecular recognition element, SWCNT can act as optical sensors that respond sensitively and specifically to a target analyte. Both antibodies and DNA aptamers can serve as molecular recognition probes, but aptamers may hold advantages for certain sensing applications due to their smaller size, higher stability, and lower production cost. We functionalized SWCNT with an analyte-specific DNA aptamer, which resulted in a nanosensor which responds selectively to IL-6. In vitro testing revealed significant shifts in the center wavelength and intensity of SWCNT fluorescence in response to IL-6. We then conducted several studies to investigate the mechanism of this sensor response in order to compare against traditional antibody-based sensors prior to ex vivo clinical sample testing. Rapid, minimally invasive detection of IL-6 as a chronic disease biomarker in vivo through DNA aptamer-functionalized SWCNT holds promise for early disease diagnosis, observation of disease progression, and evaluation of response to therapy.

European Medicines Agency Conflicts With the European Food Safety Authority (EFSA) on Bisphenol A Regulation.

The European Food Safety Authority (EFSA) has revised their estimate of the toxicity of bisphenol A (BPA) and, as a result, have recommended reducing the tolerable daily intake (TDI) by 20 000-fold. This would essentially ban the use of BPA in food packaging such as can liners, plastic food containers, and in consumer products. To come to this conclusion, EFSA used a systematic approach according to a pre-established protocol and included all guideline and nonguideline studies in their analysis. They found that Th-17 immune cells increased with very low exposure to BPA and used this endpoint to revise the TDI to be human health protective. A number of regulatory agencies including the European Medicines Agency (EMA) have written formal disagreements with several elements of EFSA's proposal. The European Commission will now decide whether to accept EFSA's recommendation over the objections of EMA. If the Commission accepts EFSA's recommendation, it will be a landmark action using knowledge acquired through independent scientific studies focused on biomarkers of chronic disease to protect human health. The goal of this Perspective is to clearly articulate the monumental nature of this debate and decision and to explain what is at stake. Our perspective is that the weight of evidence clearly supports EFSA's proposal to reduce the TDI by 20 000-fold.

Epidermal Wearable Biosensors for the Continuous Monitoring of Biomarkers of Chronic Disease in Interstitial Fluid.

Healthcare technology has allowed individuals to monitor and track various physiological and biological parameters. With the growing trend of the use of the internet of things and big data, wearable biosensors have shown great potential in gaining access to the human body, and providing additional functionality to analyze physiological and biochemical information, which has led to a better personalized and more efficient healthcare. In this review, we summarize the biomarkers in interstitial fluid, introduce and explain the extraction methods for interstitial fluid, and discuss the application of epidermal wearable biosensors for the continuous monitoring of markers in clinical biology. In addition, the current needs, development prospects and challenges are briefly discussed.

P28-020-23 The Impact of Foods Away From Home on Dietary Intake and Chronic Disease Biomarkers

P28-020-23 The Impact of Foods Away From Home on Dietary Intake and Chronic Disease Biomarkers

Epidermal Wearable Biosensors for Monitoring Biomarkers of Chronic Disease in Sweat

Biological information detection technology is mainly used for the detection of physiological and biochemical parameters closely related to human tissues and organ lesions, such as biomarkers. This technology has important value in the clinical diagnosis and treatment of chronic diseases in their early stages. Wearable biosensors can be integrated with the Internet of Things and Big Data to realize the detection, transmission, storage, and comprehensive analysis of human physiological and biochemical information. This technology has extremely wide applications and considerable market prospects in frontier fields including personal health monitoring, chronic disease diagnosis and management, and home medical care. In this review, we systematically summarized the sweat biomarkers, introduced the sweat extraction and collection methods, and discussed the application and development of epidermal wearable biosensors for monitoring biomarkers in sweat in preclinical research in recent years. In addition, the current challenges and development prospects in this field were discussed.

Magnetic Large‐Mesoporous Nanoreactors Enable Enzymatically Regulated Background‐Free and Persistently Signalling Diseases Diagnosis

AbstractDiverse diseases and increasing prevalence pose a serious threat to public health. Point‐of‐care testing (POCT) techniques have imposed superior requirements over sensitivity, selectivity, robustness, affordability, and high‐throughput. However, transient signal, complex sample pretreatment, and low signal‐to‐noise ratio make POCT severely limited in detection accuracy, efficiency, and sensitivity. Here, an enzyme‐assisted magnetic large‐mesoporous nanoreactor (FS) is constructed for achieving persistent‐chemiluminescence signal output and eliminating matrix interference in disease diagnosis. The core‐shell structured FS synthesized via an interface coassembly method exhibits uniform size, large and open mesopores (≈22 nm), and intrinsic magnetic separability. Such unique FS acts as efficient nanoreactor for confined cascade reactions enable efficient persistent‐chemiluminescence (pCL) signal transduction and high‐SNR chromogenic analysis of diverse biomarkers. The developed pCL assays facilitate high‐sensitive determination of chronic disease biomarkers glucose and uric acid with detection limits (DL) of 5.4 mg L−1 and 151.2 ng L−1, respectively. The proposed chromogenic immunoassay enables an ultrasensitive and visual determination of alpha‐fetoprotein with a DL of 1.2 ng L−1, which is superior to previously published immunoassays. The feasibility of the developed methods for real‐world applications are demonstrated in 159 clinical serum samples, and the determination results agree well with the clinical data. The proposed technique is expected to promote highly sensitive disease diagnosis in primary medical institutions and resource‐limited areas since not relying on expensive automatic sampling and testing instruments. The good flexibility of the customizable nanoreactor makes it a powerful tool for developing various POCT techniques for rapid, sensitive, and accurate diseases diagnosis.

Mitochondrial DNA Copy Number: Linking Diabetes and Cancer.

Recent Advances: Various studies have suggested that mitochondrial DNA copy number (mtDNA-CN), a surrogate biomarker of mitochondrial dysfunction, is an easily quantifiable biomarker for chronic diseases, including diabetes and cancer. However, current knowledge is limited, and the results are controversial. This has been attributed mainly to methodology and study design. Critical Issues: The incidence of diabetes and cancer has increased significantly in recent years. Moreover, type 2 diabetes (T2D) has been shown to be a risk factor for cancer. mtDNA-CN has been associated with both T2D and cancer. However, it is not known whether mtDNA-CN plays any role in the association between T2D and cancer. Significance: In this review, we have discussed mtDNA-CN in diabetes and cancer, and reviewed the literature and methodology used in published studies so far. Based on the literature review, we have speculated how mtDNA-CN may act as a link between diabetes and cancer. Furthermore, we have provided some recommendations for reliable translation of mtDNA-CN as a biomarker. Future Directions: Further research is required to elucidate the role of mtDNA-CN in the association between T2D and cancer. If established, early lifestyle interventions, such as physical activity and diet control that improve mitochondrial function, may help preventing cancer in patients with T2D. Antioxid. Redox Signal. 37, 1168-1190.

Associations of Bone Mineral Density with RANKL and Osteoprotegerin in Arab Postmenopausal Women: A Cross-Sectional Study.

Background and objective: There is limited information as to the association of several key bone markers with bone mineral density (BMD) in understudied ethnic groups. This study investigated the relationship between circulating levels of osteoprotegerin (OPG) and receptor activator of nuclear factor kappa-Β ligand (RANKL) with BMD in Arab postmenopausal women. Materials and methods: In this cross-sectional study, a total of 617 Saudi postmenopausal women from the Osteoporosis Registry of the Chair for Biomarkers of Chronic Diseases were included. Anthropometric data, BMD, and biochemical data were retrieved from the registry. Participants were stratified into three groups based on T-score; n = 169 with osteoporosis, n = 282 with osteopenia, and n = 166 normal. Analysis of bone markers including RANKL, OPG, osteocalcin, and N-terminal telopeptide (NTx) was completed using commercially available bioassays. Results: The results suggested that OPG was significantly and positively correlated with age in the osteoporosis group (r = 0.29, p < 0.05), while it was inversely correlated with BMD femoral neck left (r = −0.56, p < 0.001) and BMD femoral neck right (r = −0.37, p < 0.05) in the same group. Moreover, RANKL showed a significant inverse correlation with NTx in the osteopenia group (r = −0.37, p < 0.05). Furthermore, the RANKL/OPG ratio had a positive and significant correlation with BMI (r = 0.34, p < 0.05), BMD femoral neck left (r = 0.36, p < 0.05) and BMD femoral neck right (r = 0.35, p < 0.05) in the osteopenia group. By contrast, it showed a significant inverse correlation with waist to hip ratio in the osteoporosis group (r = −0.38, p < 0.05). Multiple regression analysis showed that OPG contributes to BMD variations in the osteopenia group (p = 0.03). Conclusions: In conclusion, changes in circulating levels of RANKL and OPG might be a protective mechanism contrary to the increased bone loss in postmenopausal women.

Viscoelastic and viscoplastic Glucose Theory (VGT #26): Investigation of the Relationships between an Overall Metabolism Index and type 2 Diabetes Utilizing HbA1C, Diabetic Nephropathy via Urinary Albumin-to-Creatinine Ratio, along with Diabetic Retinopathy with Hypothyroidism through Thyroid Stimulating Hormone using Statistical Correlation Coefficient and VGT of GH-Method: Math-Physical Medicine (No. 607)

Over the past two years, the author self-studied certain biomarkers and their relationships with certain diabetic complications, such as albumin-to-creatinine ratio (ACR) for diabetic nephropathy, thyroid stimulating hormone (TSH) for hypothyroidism and diabetic retinopathy (DR). The medical papers he reviewed utilized statistical tools, including regression analysis, with input data collected from hundreds of different patients in hospitals (References 1-14). In this article, he uses his own collected data from the past ~9 years, where he applies a combined math-physical medicine tools, such as correlations (a statistics tool), viscoelastic and viscoplastic glucose theory (VGT, a physics tool) from engineering, and perturbation theory from quantum mechanics to investigate certain hidden behaviors of selected biomarkers, such as MI, HbA1C, ACR, TSH, and their associated diseases. Initially, he attempts to find relationships between two biomarkers, ACR and TSH. Although these two biomarkers belong to output variables of the human body, he tries to alter their roles with the following two assumptions: TSH influences ACR and ACR influences TSH. He then selects the metabolism index (MI) as the sole input variable of all outputs for endocrinological diseases, including diabetes, chronic kidney disease (CKD), and diabetic retinopathy (DR). The MI is an integrated value from 10 selected categories: weight, glucose, blood pressure, blood lipid, diet, exercise, stress, sleep, water intake, and daily life routines. Next, he utilizes the general health status unit (GHSU), which is the 90-days moving average value of MI for this analysis. The logic behind this decision is that MI, chronic disease biomarkers and lifestyle details, influences type 2 diabetes (T2D) which in turn impacts various diabetic complications, including CKD (ACR as biomarker), DR and hypothyroidism (TSH as biomarker). In summary, the research path from GHSU (or MI) to T2D, then from GHSU to ACR or CKD, and GHSU to TSH or DR. Along this biomedical pathway, the following six key findings are observed: (1) The correlation between GHSU and Daily A1C is 82% within a period from 5/29/2018 to 2/15/2022. But, the correlation between Daily A1C and lab-tested A1C is 74% over 16 discrete dates. Both correlations are quite high which indicates that the overall metabolism is indeed strongly influencing T2D conditions.

Editorial

This special section gives the opportunity to know recent advances in the application of intelligent optimization algorithms in genomics and precision medicine. Precision medicine is designed to optimize the pathway for diagnosis, therapeutic intervention, and prognosis by using multidimensional biological datasets that capture individual variability in genes, function, and environment. Recent advances in -omics technologies provide substantial novel opportunities to study and/or identify biomarkers of chronic diseases by interpreting multi-omics data, including transcriptomics, epigenomics, genomics, and proteomics, that, together may improve understanding of precision medicine. Precision medicine is drugs or treatments designed for small groups, rather than large populations, based on characteristics, such as medical history, genetic makeup, and data recorded by wearable devices. The use of genomic data can support precision medicine to enable clinicians to predict the most appropriate course of action quickly, efficiently, and accurately for a patient. This offers clinicians the opportunity to tailor early interventions to each patient more carefully.

Graphene-Based Biosensors for Molecular Chronic Inflammatory Disease Biomarker Detection.

Chronic inflammatory diseases, such as cancer, diabetes mellitus, stroke, ischemic heart diseases, neurodegenerative conditions, and COVID-19 have had a high number of deaths worldwide in recent years. The accurate detection of the biomarkers for chronic inflammatory diseases can significantly improve diagnosis, as well as therapy and clinical care in patients. Graphene derivative materials (GDMs), such as pristine graphene (G), graphene oxide (GO), and reduced graphene oxide (rGO), have shown tremendous benefits for biosensing and in the development of novel biosensor devices. GDMs exhibit excellent chemical, electrical and mechanical properties, good biocompatibility, and the facility of surface modification for biomolecular recognition, opening new opportunities for simple, accurate, and sensitive detection of biomarkers. This review shows the recent advances, properties, and potentialities of GDMs for developing robust biosensors. We show the main electrochemical and optical-sensing methods based on GDMs, as well as their design and manufacture in order to integrate them into robust, wearable, remote, and smart biosensors devices. We also describe the current application of such methods and technologies for the biosensing of chronic disease biomarkers. We also describe the current application of such methods and technologies for the biosensing of chronic disease biomarkers with improved sensitivity, reaching limits of detection from the nano to atto range concentration.